Gallium Maltolate Found Effective Against the COVID-19 Virus
December 23, 2020 ♦ A published, peer-reviewed study has found gallium maltolate (GaM) to be effective against the COVID-19 virus (SARS-CoV-2), while being harmless to host cells. In vitro activity against the virus was reported at GaM concentrations attainable with oral dosing. Previous experiments have demonstrated potent anti-inflammatory activity for gallium, without suppression of normal immune responses. Most relevantly, gallium was highly effective in an animal model of septic shock, a commonly fatal inflammatory reaction to bacterial infection that is similar in many respects to the dangerous hyperinflammatory reaction associated with severe cases of COVID-19. Orally administered GaM has successfully completed several Phase 1 clinical trials, both in healthy volunteers and in advanced cancer patients. Funding and sites for a clinical trial of oral GaM in COVID-19 patients are being sought. Please contact us if you can help. Thank you! The full article can be viewed here: Bernstein and Zhang, 2020.
Gallixa® skin cream reported to speed and improve wound healing in horses
June 20, 2020 ♦
A newly published study found that Gallixa® skin cream accelerated the healing of lower leg wounds in horses, as well as reducing infection. The study, by equine veterinarians at the Texas A&M College of Veterinary Medicine & Biomedical Sciences, measured the healing rate, the quality of healing (indicated by the amount of granulation tissue, which can interfere with normal healing), and the amount of bacterial infection, against similar untreated wounds. In all respects, Gallixa® skin cream (topical gallium maltolate 0.5%) was found effective and beneficial. The full paper can be accessed here: Lawless et al., 2020.
New publication reports that topical gallium maltolate kills drug-resistant bacteria
May 1, 2019 ♦
A new scientific paper, "Bactericidal activity of 3D-printed hydrogel dressing loaded with gallium maltolate" (APL Bioengineering 2019 3:2), reports that topical dressings containing gallium maltolate effectively treated skin infections in mice caused by Staphylococcus aureus. Even infections caused by the highly drug-resistant MRSA (methicillin-resistant Staphylococcus aureus) strain were effectively treated. In vitro studies also demonstrated the antibacterial activity of gallium maltolate. The paper suggests that hydrogel dressings containing gallium maltolate could provide an improved method for treating chronic wounds, which "are projected to reach epidemic proportions" in the near future.
Gallixa skin cream effective in a rabbit model of yaws
January 14, 2019 ♦
A published scientific paper reports that Gallixa® skin cream was effective at treating yaws in rabbits. Yaws is a tropical infectious disease that initially produces skin ulcers, and then progresses to produce lesions in the joints and bones. The disease is caused by a subspecies of the infectious agent for syphilis (Treponema pallidum), for which gallium was also reported (in 1931 at the Pasteur Institute in Paris) to be effective in animal models. Experiments found that Gallixa® skin cream killed the causative bacteria and helped prevent the development of skin lesions. Further animal and human testing is planned to determine if the product could be useful in treating yaws, which causes widespread disfigurement and disability in many tropical regions. Experiments are also planned to determine the efficacy of oral gallium maltolate against yaws and syphilis.
Gallixa proposed as possible alternative to opioids at World Congress on Pain
September 16, 2018 ♦ At the World Congress on Pain in Boston, Massachusetts, Gallixa presented a series of case studies on patients who were taking opioids (such as morphine or oxycodone) for either severe chronic neuropathic pain or migraine headache. These patients, some of whom had been taking opioids for years, were able to entirely discontinue their opioid use by regularly applying Gallixa skin cream. No adverse events of any kind were reported. The poster presentation can be viewed at: IASP 2018 Gallixa Poster Presentation. The biannual World Congress on Pain is the largest gathering of pain researchers in the world, attracting over 8,000 people this year.
Update from Ontario, Canada
February 1, 2017 ♦
An update about Gallixa was received today from Dave Stewart of Hamilton, Ontario, Canada. Dave has been using Gallixa for a couple of years, and also has been distributing some to his friends and neighbors. These are his reports on individuals who have tried the product:
"A woman who couldn't bend her knee for two weeks due to pain was bending it and walking normally after 5 minutes when she used the cream. She was doing housework pain free 4 hrs later when I called to see how she was doing.
"A 100 plus year old woman with fingers as large as sausages and could not touch her palm due to stiffness and pain, bent and touch her palm within minutes of using the cream.
"A senior with crippling arthritis in both hands almost begged to have some cream for her second hand once she felt relief on the first using the cream.
"A man who was severely injured and had nerve damage so he could not walk straight or straighten his hands out properly or close them without having sever spasms throughout his body was able to close his hand without pain and without having spasms at all.
"A man who after an accident could not use even the purest hand creams like Nivea without breaking into a rash, used Gallixa and had no rash but did have pain relief and freer movement in his hands."
Positive clinical results on Gallixa presented at World Congress on Pain
September 27, 2016 ♦ Highly positive clinical results for Gallixa skin cream (topical gallium maltolate) were presented at the 16th World Congress on Pain in Yokohama, Japan. The scientific presentation reported that Gallixa was used to treat four patients who had severe neuropathic pain following orofacial surgery and/or radiation therapy, and whose pain had not responded to available therapies. Gallixa was highly and rapidly effective, commonly eliminating all pain. The poster presentation can be viewed at: IASP 2016 Gallixa Poster Presentation
European patent granted for the use of gallium to treat neuropathic pain
May 6, 2016 ♦ The European Patent Office has granted a European patent to Gallixa founder Lawrence R. Bernstein, claiming "A pharmaceutical composition comprising a pharmaceutically acceptable gallium compound and a carrier suitable for local administration for the treatment of pain by administration to a painful region, to tissues adjacent to the painful region, or to tissues in or adjacent to the region from which the pain is referred wherein the pain is neuropathic pain". Further details are available at:
Gallixa 2016 European pain patent
Gallixa to present at the 16th World Congress on Pain, Yokohama, Japan
March 14, 2016 ♦ We will be making a scientific presentation at the 16th World Congress on Pain to be held at Yokohama, Japan on September 26-30, 2016. The presentation will be titled, "Efficacy of topical gallium maltolate for neuropathic orofacial pain following surgery or radiotherapy". More details to come!
Gallixa presenting at TNA National Conference in New York City, Oct. 10-11, 2015
Gallixa® receives patent for treatment of pain associated with cancer treatment
August 25, 2015 ♦ The sixth patent covering the local administration of gallium compositions to treat pain or skin disorders was issued to Dr. Lawrence R. Bernstein, the creator of Gallixa skin cream. This patent, U.S. Patent 9,114,067, pertains to the use of gallium compositions, including gallium maltolate (the novel ingredient in Gallixa), to treat pain associated with cancer treatments. Cancer is generally treated using surgery, radiation therapy, and chemotherapy, all of which can leave the patient in pain. This pain, commonly resulting from nerve damage (neuropathic pain), is usually difficult to treat with conventional therapies. Other issued patents related to Gallixa have covered the use of gallium to treat neuropathic pain in general (including pain associated with cancer itself, plus trigeminal neuralgia, postherpetic neuralgia, and diabetic neuropathy) as well as pain associated with burns, allergic reactions, and sensitivity reactions. An earlier patent covered the use of gallium maltolate to treat skin disorders, such as psoriasis, acne, and actinic keratosis. Further patents are pending.
Podiatrist relieves his own chronic foot pain with Gallixa®
July 7, 2015 ♦
Dr. Grigoriy N. Patish, a podiatrist who practices at Fallbrook Podiatry in Fallbrook, California, was recently attending a family function in Seattle, Washington when his chronic foot pain (tibialis posterior tendinitis) flared up severely. One of his cousins, who had recently purchased some Gallixa skin cream, offered him some to try. Within minutes, Dr. Patish experienced great pain relief and was able to stand and walk again. A couple of days later, he reports that his foot pain, which he had experienced for years, had diminished by 80% after "only three applications", calling Gallixa skin cream "amazing" and "remarkable". Dr. Patish says that he will be enthusiastically recommending Gallixa skin cream to his patients.
Ordering Gallixa® online now more convenient and secure
June 10, 2015 ♦
The Gallixa website now has its own easy-to-use shopping cart for faster, easier shopping—clicking the "Buy Gallixa" button takes you right there. You can quickly and easily pay with a credit card—Visa, MasterCard, AmEx, Discover, or JCB—or any debit card with the Visa or MasterCard logos. You can also go directly to Amazon (via the "Checkout with Amazon" button) or PayPal and pay from your account. In addition, the entire website, including the shopping cart, is now protected with dedicated SSL ("Secure Sockets Layer") encryption, providing a secure, private connection between you and the website.
Gallixa® reported to produce continued improvement after five months
May 18, 2015 ♦
As previously reported, Michigan woman Dawn Monarch had been experiencing excruciating facial pain (trigeminal neuralgia) for 20 years. Even the slightest breeze would trigger the pain. To reduce the pain, she took morphine and other powerful prescription pain medications every day. In December, 2014 she started using Gallixa skin cream, which she said produced rapid and strong pain relief. Five months later, Dawn reports that, with continued use of Gallixa, her facial pain has been brought completely under control and she has stopped using all pain medications. Even the burning pain in her mouth she says has been reduced by 85%. Her sister, Sandra, describes Dawn's improvement as amazing, saying that she is like a new person. Previously, Dawn could hardly leave her room and couldn't even touch her own face; now, she is out leading an active life, and her young niece can draw pictures on her face!
Gallixa® makes the news!
December 7, 2014 ♦ A Michigan woman's experience with Gallixa was reported in the December 7th edition of The Battle Creek Enquirer. The story related how the woman (Dawn Monarch) had suffered with trigeminal neuralgia pain for 20 years, despite treatment with narcotics, and then experienced remarkable pain relief after using Gallixa skin cream. The story can be read here: "New Product Brings Monarch Relief"
Gallixa® receives patent for treatment of pain associated with hemorrhoids
October 28, 2014 ♦ The fifth patent covering the local administration of gallium compositions to treat pain or skin disorders was issued to Dr. Lawrence R. Bernstein, the creator of Gallixa skin cream. This patent, U.S. Patent 8,871,246, pertains to the use of gallium compositions, including gallium maltolate (the novel ingredient in Gallixa), to treat pain associated with hemorrhoids. Previously issued patents have covered other types of pain, including neuropathic pain such as trigeminal neuralgia and postherpetic neuralgia, as well as pain associated with burns, allergic reactions, and sensitivity reactions. An earlier patent covered the use of gallium maltolate to treat skin disorders, such as psoriasis and actinic keratosis. Further patents are pending.
Successful use of Gallixa® to treat trigeminal neuralgia reported at the 15th World Congess on Pain
October 10, 2014 ♦ Research results demonstrating significant relief of trigeminal neuralgia pain from the use of Gallixa were presented today at the Fifteenth World Congess on Pain in Buenos Aires, Argentina. The poster presentation by Dr. Lawrence R. Bernstein reported substantial pain relief in all 14 trigeminal neuralgia subjects treated with Gallixa (topical gallium maltolate), with no reported adverse effects. All the subjects in the study experienced trigeminal neuralgia pain that had persisted despite previous medical and/or surgical treatment. The biennial World Congress on Pain brings together pain researchers and clinicians in the world's largest gathering of pain specialists.
Gallixa® reported effective against TMJ pain
August 1, 2014 ♦ Laurie Weinroth, a Toronto resident who suffers from facial pain due to both TN (trigeminal neuralgia) and TMJ (temporomandibular joint dysfunction), previously reported that Gallixa is highly effective for his TN. He has now found that Gallixa can also relieve his TMJ pain: "At 8:36 PM today, I was timing it, I had severe pain owing to TMJ, crushing pain. I applied Gallixa twice, very thickly along my cheekbone and ear, and within six minutes, still have a dull pain, but I would posit the pain has been reduced by about 75%." The following day he provided an update, saying, "Does not hurt today, quite a discovery!"
New review article on trigeminal neuralgia published by international pain research organization
June 27, 2014 ♦ A thoughtful, comprehensive review of the latest information on trigeminal neuralgia was recently published by the International Association for the Study of Pain. This review, The Patient’s Journey Through Trigeminal Neuralgia, is unusual is that it is written by a physician and a researcher, primarily for physicians, but from a patient's point of view. The intention is to make the medical community more aware not only of the disease, but also of the struggles of patients who endure both the pain and, commonly, a poorly responsive healthcare system. For your convenience, the article is posted on the Gallixa website; you can click on the link above to read it.
Topical gallium maltolate (Gallixa®) is among "five best treatments for trigeminal neuralgia" according to posting by physician
February 21, 2014 ♦ A physician with Arizona Injury Medical Associates (AIMA) lists topical gallium maltolate (Gallixa®) as one of the "five best treatments for trigeminal neuralgia" on the AIMA website. (Gallixa LLC is not affiliated in any way with the physician or AIMA.) Gallixa LLC frequently receives reports from people whose trigeminal neuralgia pain is relieved by Gallixa®, even when other therapies have not been effective.
People with diabetic foot pain report pain relief from Gallixa®
January 18, 2014 ♦ Pain in the hands and particularly feet is a common symptom of people who have diabetes. Several individuals who suffer from this condition, which is termed painful diabetic neuropathy, have reported great pain relief from Gallixa, even when other treatments had proven ineffective. Most recently, Marlene Eckhardt of Capitola, California, said that the diabetes-induced pain, burning, and tingling in her feet have been so much relieved by Gallixa that her abilities to sleep and to walk have greatly improved. Gallixa was recommended to her by her doctor, and she has been using it daily for several months.
Gallixa® not just for people?
October 29, 2013 ♦ A noted equine veterinarian, Dr. Ursula Fogarty of the Irish Equine Centre in County Kildare, Ireland, reports that daily application of Gallixa to a growing skin cancer (sarcoid) on a horse produced remarkable tumor regression and healing in only seven days. "Before" and "after" photos can be viewed in the following link, but be aware that the untreated tumor is unpleasant looking: equine sarcoid photos. Also, racehorse trainer and owner Ian Howard reports that Gallixa applied to a large open wound on a horse produced rapid healing, with none of the complications usually seen in such situations: horse wound photos.
U.S. Army veteran nurse experiences rapid relief of facial pain from Gallixa®
September 30, 2013 ♦ Ms. Larrietta (Jae) Johnson, a nurse who served more than 10 years with the 67th Combat Support Hospital of the US Army, reported that Gallixa provides rapid relief of pain from her trigeminal neuralgia. She says that Gallixa greatly decreases her facial and mouth pain within minutes, allowing her to eat, sleep, and "return to an ordinary day of work". If she has pain when eating or drinking, "a small application of Gallixa and I am as good as new again"; at night, "I get total relief". UPDATE: October 2, 2013 ♦ "The cream is working so well that I have not had to take any Neurontin [pain medication] at all!"
Anti-pathogen effects of gallium were known more than 80 years ago, but have remained largely forgotten
September 25, 2013 ♦ A group of French scientists reported in 1931 that a single dose of a gallium salt cured syphilis in rabbits. They also reported that gallium prevented and cured trypanosomiasis (infection with Trypanosoma protozoan parasites) in mice, guinea pigs, and monkeys. (You can read the original paper by clicking here; an English translation is on the last page.) African trypanosomiasis (sleeping sickness) and South American trypanosomiasis (Chagas disease) afflict millions of people and cause thousands of deaths each year. Current treatments for these diseases are of limited efficacy, are commonly dangerous, or are difficult to administer. Dr. Lawrence Bernstein, creator of Gallixa skin cream, is working with a new nonprofit organization to revive research on the possible use of gallium as a safe, inexpensive alternative to treat these neglected diseases of the developing world.
Woman reports that Gallixa® was effective against a resistant wart
September 5, 2013 ♦ A woman in Maryland reported that Gallixa eliminated a wart on her finger that had not succumbed to other treatments. Prior to trying Gallixa, she had used salicylic acid, freezing, and duct tape (alone and in combination) without success. Gallixa painlessly and neatly "dissolved" away the wart in only about a week of daily use. Warts are caused by human papillomaviruses (HPV), and gallium is known to be effective against certain other viruses (such as HIV). Although there are currently no reported scientific data on the efficacy of gallium against HPV, efficacy against these viruses is a possibility.
Gallixa® now has no added preservatives, is creamier, and is available in both a 1.2-oz jar and a 2-oz tube
September 3, 2013 ♦ Gallixa has been reformulated to be creamier and smoother to apply. Because it now contains no added preservatives, it is hypoallergenic. Gallixa is available in 1.2 ounce jars (20% larger than before, but at the same low price), and also in convenient 2-ounce tubes. As always, gallium maltolate and Gallixa are made in the USA under FDA standards (Current Good Manufacturing Practices).
Gallixa® is awarded a new U.S. patent
August 13, 2013 ♦ A new U.S. patent was granted to Gallixa LLC owner Lawrence R. Bernstein, Ph.D., for the use of gallium compounds, including gallium maltolate, to treat pain. The new patent, US 8,506,990, is the third patent granted to Dr. Bernstein regarding the local administration of gallium compositions to treat pain. An additional patent, US 5,747,482, claims the use of gallium maltolate to treat inflammatory and proliferative skin conditions, including psoriasis, acne, seborrhea, eczema, and actinic keratosis. Additional patents are pending.
Gallixa is now Gallixa®
July 16, 2013 ♦ The name "Gallixa" has been officially registered as a trademark by the U.S. Patent and Trademark Office. The trademark applies to a wide variety of skin products.
Gallixa lowers international shipping rates
June 29, 2013 ♦ Gallixa is now able to offer lower shipping rates to Canada and other countries outside of the United States. Some of the rates are 50% lower than previously, available as First-Class International Mail through the U.S. Postal Service. Delivery times and tracking are nearly the same as for Priority International Mail. Rates are available on the Gallixa Policies page.
Gallixa provides the first significant reduction of a woman's severe, intractable facial pain in 20 years
June 28, 2013 ♦ A woman in North Carolina had suffered from extreme facial pain due to postherpetic neuralgia (pain than persists following a bout of shingles) since 1993. Even though she had been taking daily morphine and antidepressants, her pain had remained at a level of 7 on a 10-point scale. Gallixa lowered the pain from 7 to 2 in 20 minutes; a week later, with continued use of Gallixa, the woman is "essentially pain-free" for the first time in 20 years. A testimonial appears on the Endorsements page.
New data on topical gallium maltolate presented at scientific conference on neuropathic pain
May 27, 2013 ♦ Data on the analgesic properties of topical gallium maltolate were presented at the 4th International Congress on Neuropathic Pain, Toronto, Canada, May 23rd-26th, 2013. The poster presentation can be viewed here.
A patient who experienced remarkable pain relief from Gallixa is interviewed by her doctor
April 14, 2013 ♦ Dr. Richard J. McAlister interviews his patient, a woman who experienced what she called "miraculous" pain relief from Gallixa of her severe foot pain, on this video:
Please note that the statements and products shown on this website have not been evaluated by the U.S. Food and Drug Administration. Gallixa® is not intended to diagnose, treat, cure, or prevent any disease or condition.